The first human alpha-spectrin structural domain begins with serine. 1994

D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
Department of Chemistry, Loyola University of Chicago, Illinois 60626.

The 106-amino acid sequence motifs of spectrin have been suggested to fold into stable structural domains, consisting mostly of coiled coils of triple helices. With the advent of molecular biology and biophysical techniques, structural studies of these spectrin 106-amino acid structural domains became approachable. However, one of the difficulties in such an approach is determination of the correct phasing of the structural domains, which may or may not coincide with the phasing of the sequence motifs. Proper identification of the domain phasing is vital to the construction of stable spectrin domains for molecular studies. A previously published phasing shift for Drosophila alpha-spectrin indicated a downstream phase-shift of 26 amino acids for the structural domain (Winograd, E., Hume, D., and Branton, D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10788-10791). Using this phase-shift, we prepared a recombinant spectrin peptide with the sequence from residue 49 to residue 155 of human erythrocyte alpha-spectrin and found this peptide to be unstable relative to other peptides that we prepared. Using several other recombinant alpha-spectrin peptides and following the protease digestion approach, we digested spectrin peptides with elastase and chymotrypsin and analyzed the amino acid sequence of the digestive products. We provide the first experimental evidence in identifying the first amino acid residue of the first spectrin domain in human erythrocyte alpha-spectrin as residue 52 (Ser).

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D012694 Serine A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids. L-Serine,L Serine
D013049 Spectrin A high molecular weight (220-250 kDa) water-soluble protein which can be extracted from erythrocyte ghosts in low ionic strength buffers. The protein contains no lipids or carbohydrates, is the predominant species of peripheral erythrocyte membrane proteins, and exists as a fibrous coating on the inner, cytoplasmic surface of the membrane. alpha-Spectrin,beta-Spectrin,alpha Spectrin,beta Spectrin

Related Publications

D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
January 1984, Progress in clinical and biological research,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
March 1986, Biochimica et biophysica acta,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
June 2003, The Journal of biological chemistry,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
April 1986, Biochimica et biophysica acta,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
December 1983, The Journal of biological chemistry,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
July 1993, Blood,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
December 1999, Journal of biomolecular NMR,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
October 2010, Blood,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
August 1987, FEBS letters,
D M Lusitani, and N Qtaishat, and C C LaBrake, and R N Yu, and J Davis, and M R Kelley, and L W Fung
August 1990, The Journal of clinical investigation,
Copied contents to your clipboard!